According to published data, mutations of RAS family genes (KRAS, NRAS, BRAF) occur in less than 10% in MGUS, in 50% of symptomatic MM, and in more than 70% of cases of plasma-cell leukemia, which indicates activation of this pathway in the progression of the disease [7,27]. This evidence concerns the gene KRAS and Miyoshi myopathy.